Zacks Investment Research lowered shares of TherapeuticsMD (NASDAQ:TXMD) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

Several other research firms have also recently issued reports on TXMD. BidaskClub upgraded shares of TherapeuticsMD from a strong sell rating to a sell rating in a research note on Wednesday, October 25th. Cantor Fitzgerald restated a buy rating and set a $28.00 target price on shares of TherapeuticsMD in a research note on Sunday, January 7th. Noble Financial restated a buy rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the company a buy rating in a research note on Monday, October 16th. Finally, Deutsche Bank set a $9.00 target price on shares of TherapeuticsMD and gave the company a buy rating in a research note on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $14.50.

TherapeuticsMD (NASDAQ TXMD) traded down $0.09 on Friday, reaching $6.15. 1,298,000 shares of the company’s stock traded hands, compared to its average volume of 2,680,000. The company has a market cap of $1,330.00, a PE ratio of -15.77 and a beta of 1.06. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The business had revenue of $4.42 million for the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The business’s revenue for the quarter was down 19.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.13) EPS. sell-side analysts anticipate that TherapeuticsMD will post -0.37 earnings per share for the current year.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, December 8th. The stock was purchased at an average price of $6.21 per share, with a total value of $31,050.00. Following the transaction, the director now directly owns 3,555 shares of the company’s stock, valued at $22,076.55. The purchase was disclosed in a document filed with the SEC, which is available through this link. 23.92% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TXMD. Schwab Charles Investment Management Inc. increased its position in shares of TherapeuticsMD by 10.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock valued at $3,659,000 after purchasing an additional 67,855 shares during the last quarter. Rhumbline Advisers increased its position in shares of TherapeuticsMD by 3.5% during the 2nd quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock valued at $967,000 after purchasing an additional 6,232 shares during the last quarter. Legal & General Group Plc increased its position in shares of TherapeuticsMD by 6.5% during the 2nd quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock valued at $298,000 after purchasing an additional 3,441 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after purchasing an additional 818 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of TherapeuticsMD by 72.9% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 71,706 shares of the company’s stock valued at $378,000 after purchasing an additional 30,240 shares during the last quarter. 73.69% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/01/13/zacks-investment-research-lowers-therapeuticsmd-txmd-to-sell.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.